Skip to main content
Daniel Morgensztern, MD, Oncology, Saint Louis, MO

Daniel Morgensztern MD


Associate Professor, Washington University School of Medicine, St. Louis, MO.

Join to View Full Profile
  • 4921 Parkview Pl# DvSaint Louis, MO 63110

  • Phone+1 800-647-2098

  • Fax+1 314-362-3192

Dr. Morgensztern is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Miami/Jackson Health System
    University of Miami/Jackson Health SystemResidency, Internal Medicine, 1998 - 2001
  • Tech- Ed Fndn Souza Marques Sch Med
    Tech- Ed Fndn Souza Marques Sch MedClass of 1995

Certifications & Licensure

  • MO State Medical License
    MO State Medical License 2013 - 2026
  • CT State Medical License
    CT State Medical License 2010 - 2013
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Recurrent WNT Pathway Alterations Are Frequent in Relapsed Small Cell Lung Cancer  
    Saiama N. Waqar, Daniel Morgensztern, Robert S. Fulton, Ramaswamy Govindan, Nature

Lectures

  • Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC) after checkpoint inhibitor treatment failure. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Multicenter phase II trial of RRx-001 in previously treated SCLC. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Yale Cancer Center Evening Oncology Series: Lung Cancer 
    Yale CME, New Haven, Connecticut - 5/10/2012

Authored Content

  • Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non-Small-Cell Lung CancerFebruary 2018

Press Mentions

  • Safety and Efficacy of Zimberelimab (AB122) in Combination with Domvanalimab (AB154) and Etrumadenant (AB928) in Patients with Previously Treated Non-Small Cell Lung Cancer
    Safety and Efficacy of Zimberelimab (AB122) in Combination with Domvanalimab (AB154) and Etrumadenant (AB928) in Patients with Previously Treated Non-Small Cell Lung CancerMarch 10th, 2021
  • Adding a Vaccine to Immunotherapy in Lung Cancer: Will It Improve Outcomes?
    Adding a Vaccine to Immunotherapy in Lung Cancer: Will It Improve Outcomes?March 4th, 2019
  • Heat Biologics, Inc. (NASDAQ:HTBX) Files an 8-K Regulation FD Disclosure
    Heat Biologics, Inc. (NASDAQ:HTBX) Files an 8-K Regulation FD DisclosureFebruary 28th, 2019
  • Join now to see all

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: